VivoSeq
Cardiovascular

Venous Thromboembolism (VTE)

4

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Venous Thromboembolism (VTE) is an early-stage landscape with 4 programs across 4 companies. The most active players are Regeneron, Eli Lilly, Bristol-Myers Squibb. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

2 programs

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 34

REGN7508

Regeneron

REGN9933

Regeneron

Apixaban

Bristol-Myers Squibb

Enoxaparin

Sanofi

Approved
No programs

Analysis

Trial Status

3

clinical trials

Not yet recruiting2 · 67%
Recruiting1 · 33%

Clinical Trials

Trial Activity

A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX)
Recruiting·Regeneron logoRegeneron·Phase 3·NCT07015905·2,000 enrolled
A Master Protocol for a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, for Prophylaxis of Venous Thromboembolism in Participants With a Peripherally Inserted Central Catheter (PICC) (ROXI-PEAK)
Not yet recruiting·Regeneron logoRegeneron·Phase 3·NCT07697599·1,908 enrolled
Enabling and Engaging Patients to Decide Indefinite Versus Short-Term Anticoagulation for Venous Thromboembolism (DECIDE-VTE)
Not yet recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Preclinical·NCT07659106·850 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)